tiprankstipranks
Trending News
More News >
Emergent Biosolutions (EBS)
NYSE:EBS

Emergent Biosolutions (EBS) AI Stock Analysis

Compare
1,278 Followers

Top Page

EB

Emergent Biosolutions

(NYSE:EBS)

51Neutral
Emergent Biosolutions faces financial and operational challenges with declining revenues and negative profitability. The company's significant achievements in debt reduction and operational efficiency are positive, but ongoing revenue pressures and conservative guidance weigh on the outlook. Although the technical analysis shows bearish trends, potential oversold conditions could hint at a future rebound. The valuation remains unattractive due to negative earnings.
Positive Factors
Product Development and Contracts
A contract modification for the second option period was exercised for Emergent BioSolutions' Zaire Ebola virus vaccine, valued at approximately $16.7M, indicating continued government support and investment.
Share Repurchase Program
The announcement of a share repurchase program reflects management's belief that the shares remain undervalued.
Strategic Partnerships
Rocketvax strategic relationship marks expansion of vaccine pipeline and access to novel technological approaches.
Negative Factors
Competition and Market Challenges
Risks include faster-than-anticipated NARCAN franchise erosion due to greater-than-anticipated levels of generic competition.
Revenue Performance
Emergent BioSolutions reported a moderate miss in top-line revenue, recording $1.04B compared to expectations of ~$1.12B.
Stock Performance
Investors should note that Emergent shares are down roughly 49% compared to a roughly 10% decline in the benchmark XBI index.

Emergent Biosolutions (EBS) vs. S&P 500 (SPY)

Emergent Biosolutions Business Overview & Revenue Model

Company DescriptionEmergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
How the Company Makes MoneyEmergent BioSolutions makes money through the sale of its medical countermeasures and public health products to governments, non-governmental organizations, and commercial entities. Key revenue streams include contracts with the U.S. government for the provision of biodefense products such as anthrax vaccines and treatments for chemical exposure. The company also generates revenue from the development and sale of products addressing emerging infectious diseases, such as vaccines for COVID-19. Partnerships with other pharmaceutical and biotechnology companies for product development and commercialization contribute significantly to its earnings. Additionally, Emergent BioSolutions may receive funding from government agencies and organizations to support research and development activities.

Emergent Biosolutions Financial Statement Overview

Summary
Emergent BioSolutions shows significant financial challenges with declining revenues and persistent negative net income. However, the absence of debt and recent improvements in cash flow provide some positives.
Income Statement
45
Neutral
Emergent Biosolutions has faced challenges in recent years, as evidenced by negative EBIT and net income margins. The company's revenue has been declining since 2021, and the net profit margin has been negative for the past three years. This indicates substantial operational and profitability issues. The Gross Profit Margin for the most recent year is unusually high due to the same value for total revenue and gross profit, suggesting data inconsistency or reporting issues.
Balance Sheet
55
Neutral
The balance sheet shows a strong equity position relative to liabilities, with a debt-to-equity ratio of 0. This indicates no debt burden, which is positive. However, the Return on Equity is negative due to the negative net income, reflecting poor profitability. The Equity Ratio has decreased over the years, showing a reduced proportion of equity financing.
Cash Flow
60
Neutral
While the company has managed to generate positive operating cash flow in the latest year, the free cash flow has only recently turned positive. The Operating Cash Flow to Net Income Ratio is strong due to negative net income, indicating an ability to generate cash despite accounting losses. However, historical free cash flow was negative, showing past liquidity issues.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
1.01B1.05B1.12B1.79B1.56B
Gross Profit
1.01B343.90M427.20M1.04B1.03B
EBIT
-108.70M-726.40M-166.00M352.60M433.80M
EBITDA
36.90M-505.30M-32.90M458.20M549.00M
Net Income Common Stockholders
-190.60M-760.50M-223.80M219.50M305.80M
Balance SheetCash, Cash Equivalents and Short-Term Investments
99.50M111.70M642.60M576.10M621.30M
Total Assets
1.39B1.82B3.17B2.96B2.88B
Total Debt
663.70M860.20M1.41B841.00M874.80M
Net Debt
564.20M748.50M763.20M264.90M253.50M
Total Liabilities
906.90M1.17B1.78B1.34B1.44B
Stockholders Equity
482.80M649.30M1.38B1.62B1.45B
Cash FlowFree Cash Flow
35.80M-257.90M-149.90M96.10M395.00M
Operating Cash Flow
58.70M-206.30M-34.10M321.10M536.00M
Investing Cash Flow
125.20M212.30M-381.30M-225.00M-151.00M
Financing Cash Flow
-190.00M-535.70M481.20M-141.00M69.50M

Emergent Biosolutions Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4.98
Price Trends
50DMA
5.98
Negative
100DMA
7.85
Negative
200DMA
8.55
Negative
Market Momentum
MACD
-0.37
Negative
RSI
47.52
Neutral
STOCH
81.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Negative. The current price of 4.98 is above the 20-day moving average (MA) of 4.68, below the 50-day MA of 5.98, and below the 200-day MA of 8.55, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 47.52 is Neutral, neither overbought nor oversold. The STOCH value of 81.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EBS.

Emergent Biosolutions Risk Analysis

Emergent Biosolutions disclosed 57 risk factors in its most recent earnings report. Emergent Biosolutions reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Emergent Biosolutions Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$437.91M7.5328.70%10.13%-0.86%-13.33%
65
Neutral
$1.49B-4.86%26.20%-219.22%
57
Neutral
$1.31B61.364.48%19.36%
EBEBS
51
Neutral
$256.47M-33.67%-0.62%75.57%
51
Neutral
$5.20B3.26-40.34%2.93%17.68%1.94%
44
Neutral
$228.82M-83.58%6.88%-17.54%
40
Underperform
$271.90M77.48%13.80%-389.41%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
EBS
Emergent Biosolutions
4.98
3.03
155.38%
DVAX
Dynavax
10.77
-0.40
-3.58%
LFCR
Lifecore Biomedical
6.34
-0.30
-4.52%
SIGA
SIGA Technologies
6.24
-2.40
-27.78%
ANIP
ANI Pharmaceuticals
68.37
3.42
5.27%
AQST
Aquestive Therapeutics
2.82
-1.11
-28.24%

Emergent Biosolutions Earnings Call Summary

Earnings Call Date: Mar 3, 2025 | % Change Since: -27.09% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Neutral
The earnings call presented significant achievements in financial stability and operational efficiency, highlighted by debt reduction and cost savings. However, revenue challenges, including a decline in NARCAN sales and conservative future guidance, indicate ongoing challenges. The sentiment is balanced with notable improvements offset by revenue pressures.
Highlights
Debt Reduction and Financial Stability
Emergent BioSolutions Inc. reduced net debt by $156 million (21%) and improved the balance sheet, extending debt maturity to 2029.
Improved Profitability and Cost Savings
Operating expenditures were reduced by $130 million, with a total of $250 million in savings over two years. Adjusted EBITDA improved to $183 million from a negative $22 million in 2023.
NARCAN Distribution and Market Leadership
Distributed 11 million two-dose cartons of NARCAN across the US and Canada, maintaining a 75% market share in the growing naloxone nasal spray market.
Strong Contract Awards and BioDefense Performance
Secured $550 million in MCM contract awards and maintained strong performance in biodefense product sales including anthrax and smallpox vaccines.
Lowlights
Revenue Decline
Fourth-quarter total revenues were $195 million, down from the prior year due to lower NARCAN sales and anthrax sales timing.
Conservative 2025 Guidance
2025 revenue guidance is set at $750 million to $850 million, reflecting a decrease due to transitions in governmental procurement and divestitures.
NARCAN Pricing Pressure
NARCAN experienced pricing pressures, with prices lower compared to 2023, impacting revenue despite maintaining market share.
Company Guidance
During the fourth quarter and full year 2024 earnings call, Emergent BioSolutions provided guidance for 2025, highlighting a conservative revenue forecast due to administrative transitions, with total revenue projected between $750 million and $850 million. They expect adjusted EBITDA to be in the range of $150 million to $200 million, indicating a strong margin improvement despite a lower top-line revenue. Key metrics from 2024 included total revenues of $1.04 billion and adjusted EBITDA of $183 million, with significant improvements in gross margin and a reduction in operating expenses by $130 million. The company also announced a strategic focus on their medical countermeasure (MCM) products and NARCAN nasal spray, with 2024 sales of 11 million two-dose cartons distributed across the US and Canada. They reported a net debt reduction of $156 million, ending the year with $200 million in liquidity. For 2025, they anticipate continued operational cash flow growth and strategic capital deployment to drive long-term profitable growth.

Emergent Biosolutions Corporate Events

M&A TransactionsBusiness Operations and Strategy
Emergent BioSolutions Sells Baltimore Facility to Syngene
Neutral
Mar 10, 2025

On March 10, 2025, Emergent BioSolutions announced the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million. The agreement allows Emergent to retain rights to manufacturing services at the facility for future growth and pandemic response. This transaction is part of Emergent’s multi-year transformation plan to streamline operations and enhance its manufacturing network, which includes facilities in Lansing, Michigan, and Winnipeg, Canada. The sale is expected to close in the first quarter of 2025, following customary closing conditions.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Emergent BioSolutions Reports 2024 Financial Results
Positive
Mar 3, 2025

Emergent BioSolutions reported its financial results for the fourth quarter and full year 2024, highlighting a total revenue of $1.04 billion for the year. Despite a net loss of $31.3 million in Q4, this marked a 37% improvement from the previous year. The company achieved a significant increase in adjusted EBITDA, reaching $183.1 million for the year compared to a loss in 2023, and is guiding for an adjusted EBITDA between $150 million and $200 million in 2025. Strategic actions, including debt repayment and asset divestitures, have strengthened its financial position. The company also received substantial contract awards and FDA approval for expanding the use of ACAM2000®.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.